Sculptor Capital
MLNT

Sculptor Capital’s Melinta Therapeutics, Inc. Common Stock MLNT Stock Holding History

Sculptor Capital’s Portfolio MLNT Stock Details MLNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-98,700
Closed -$376K – 354
2019
Q3 		$376K Sell
98,700
-19,800
-17% -$71.3K ﹤0.01% 265
2019
Q2 		$788K Buy
+118,500
New +$451K ﹤0.01% 221

Other funds holding MLNT

Stifel Financial
Stifel Financial St. Louis, Missouri $120B AUM 27.84% 1-Year Est. Return
Granahan Investment Management
Granahan Investment Management Waltham, Massachusetts $2.81B AUM 83.9% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
CCM
Condor Capital Management Martinsville, New Jersey $1.33B AUM 19.79% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $203M AUM 34.78% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

Sculptor Capital's MLNT Position: Q4 2019 in Review

Sculptor Capital sold out of Melinta Therapeutics, Inc. Common Stock (MLNT) in Q4 2019, closing a stake of 98,200 shares — an estimated $374K sold.

Sculptor Capital first reported a position in MLNT in Q2 2019 and held it in 2 quarters. The position peaked at $821K in Q2 2019. 37 funds tracked by Wall St. Rank hold MLNT as of Q4 2019.

  • Sculptor Capital reported no remaining Melinta Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • Sculptor Capital sold 98,200 Melinta Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $374K.
  • Sculptor Capital first reported a position in Melinta Therapeutics, Inc. Common Stock in Q2 2019 and held it in 2 quarters.
  • Sculptor Capital's Melinta Therapeutics, Inc. Common Stock position peaked at $821K in Q2 2019.
  • 37 funds tracked by Wall St. Rank held Melinta Therapeutics, Inc. Common Stock as of Q4 2019.

Based on Sculptor Capital's 13F filing for Q4 2019, filed 14 Feb 2020.